A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- NPT200-11
- Conditions
- Healthy Volunteers
- Sponsor
- Neuropore Therapies Inc.
- Enrollment
- 55
- Locations
- 1
- Primary Endpoint
- Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who meet all of the following inclusion criteria will be eligible to participate in this study:
- •informed of, and willing and able to comply with, all of the protocol requirements and the investigational nature of the study, and have signed an informed consent form in accordance with institutional and regulatory guidelines;
- •male or female adults between 18 and 55 years of age, inclusive;
- •female subjects must be post-menopausal for at least 2 years or surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation);
- •male subjects must be willing to use an adequate barrier method of contraception for the duration of the study and for 90 days after dosing and no sperm donations for the duration of the study and for 90 days after dosing. Male subjects who are surgically sterile need not employ a method of contraception;
- •non-smokers for at least six months;
- •BMI = 18 - 30 kg/m2, inclusive;
- •in good health, in the judgment of the Principal Investigator, as determined by:
- •medical history indicative of no serious or severe chronic conditions requiring frequent medical intervention or continual pharmacologic management, and no medical or social conditions that would potentially interfere with the subject's ability to comply with the study visit schedule or the study assessments;
- •no clinically significant abnormalities in body temperature, heart rate, respiratory rate, blood pressure;
Exclusion Criteria
- •Subjects who meet any of the following exclusion criteria will NOT be eligible to participate in this study:
- •females of child bearing potential;
- •history of a significant medical condition that may interfere with absorption, distribution or elimination of NPT200-11, or with the clinical and laboratory safety assessments in this study;
- •history of drug hypersensitivity and disorders affecting respiratory function (e.g., COPD, asthma) and cardiac disorders predisposing to cardiac adverse events;
- •history of or current alcohol abuse and/or other drug addiction \< 2 years prior to screening, or a positive urine drug or alcohol screen (e.g., amphetamines, barbiturates, benzodiazepines, opiates, cannabinoids, alcohol and cocaine);
- •positive for HBVsAg, HCV Ab, HIV Ab;
- •12 lead ECG showing the following: having a corrected QTc interval \> 450 msec or \<320 msec (Fridericia's correction);
- •sustained sitting systolic blood pressure \> 140 or \< 90 mm Hg or sitting diastolic blood pressure \> 90 or \< 50 mm Hg at Screening or Day -1 (sentinel pair) or Day 1 (remaining 6 subjects in the cohort), the average of the 2 assessments of BP taken at each visit will be used to exclude a subject;
- •resting pulse rate at screening of \> 100 or \< 45;
- •donated or lost \> 500 mL of blood \< 56 days prior to enrollment into this study;
Arms & Interventions
NPT200-11 - Cohort 3, Dose 3
Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 1, Dose 1
Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 1, Dose 1
Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 - Cohort 2, Dose 2
Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 2, Dose 2
Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 - Cohort 3, Dose 3
Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 - Cohort 4, Dose 4
Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 4, Dose 4
Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 - Cohort 5 ,Dose 5
Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 5 ,Dose 5
Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 -Cohort 6, Dose 6
Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 -Cohort 6, Dose 6
Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
NPT200-11 - Cohort 7, Dose 7
Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: NPT200-11
NPT200-11 - Cohort 7, Dose 7
Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
Intervention: Placebo
Outcomes
Primary Outcomes
Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests
Time Frame: Screening (28 days prior to dosing) through Day 7
Safety, as determined by the number of participants with adverse events related to treatment, the number of participants with clinically significant changes in blood pressure, heart rate and respiration, the number of participants with abnormal laboratory values, the number of participants with abnormal ECGs.
Secondary Outcomes
- To possibly determine the maximally tolerated dose (MTD) of orally administered NPT200-11 in healthy subjects.(Screening (28 days prior to dosing) through Day 7 of MTD)